{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T18:11:27Z","timestamp":1791223887044,"version":"4.1.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["L'Enc\u00e9phale"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1016\/j.encep.2014.10.009","type":"journal-article","created":{"date-parts":[[2014,11,5]],"date-time":"2014-11-05T02:52:44Z","timestamp":1415155964000},"page":"507-517","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Efficacit\u00e9 et tol\u00e9rance \u00e0 court terme de la lurasidone dans la prise en charge de la schizophr\u00e9nie"],"prefix":"10.1016","volume":"40","author":[{"given":"L.","family":"Samalin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Ben Gharbia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Garnier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.-M.","family":"Llorca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.encep.2014.10.009_bib0005","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/archpsyc.1988.01800330013001","article-title":"Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine","volume":"45","author":"Kane","year":"1988","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.encep.2014.10.009_bib0010","doi-asserted-by":"crossref","first-page":"g1173","DOI":"10.1136\/bmj.g1173","article-title":"Management of psychosis and schizophrenia in adults: summary of updated NICE guidance","volume":"348","author":"Kuipers","year":"2014","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.encep.2014.10.009_bib0015","doi-asserted-by":"crossref","first-page":"318","DOI":"10.3109\/15622975.2012.696143","article-title":"World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for biological treatment of schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance","volume":"13","author":"Hasan","year":"2012","journal-title":"World J Biol Psychiatry"},{"issue":"5","key":"10.1016\/j.encep.2014.10.009_bib0020","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1177\/0269881110391123","article-title":"Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology","volume":"25","author":"Barnes","year":"2011","journal-title":"J Psychopharmacol"},{"issue":"1","key":"10.1016\/j.encep.2014.10.009_bib0025","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/schbul\/sbp116","article-title":"The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements","volume":"36","author":"Buchanan","year":"2010","journal-title":"Schizophr Bull"},{"issue":"2","key":"10.1016\/j.encep.2014.10.009_bib0030","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1176\/appi.ajp.2008.08030368","article-title":"A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia","volume":"166","author":"Leucht","year":"2009","journal-title":"Am J Psychiatry"},{"issue":"1","key":"10.1016\/j.encep.2014.10.009_bib0035","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1093\/schbul\/sbq042","article-title":"Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons","volume":"38","author":"Rummel-Kluge","year":"2012","journal-title":"Schizophr Bull"},{"issue":"2\u20133","key":"10.1016\/j.encep.2014.10.009_bib0040","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.schres.2010.07.012","article-title":"Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis","volume":"123","author":"Rummel-Kluge","year":"2010","journal-title":"Schizophr Res"},{"key":"10.1016\/j.encep.2014.10.009_bib0045","series-title":"Drug approval package Latuda (lurasidone hydrochloride) tablets","author":"Food Drug Administration","year":"2010"},{"key":"10.1016\/j.encep.2014.10.009_bib0050","series-title":"Latuda (lurasidone HCl): monographie du produit","author":"Sunovion","year":"2014"},{"key":"10.1016\/j.encep.2014.10.009_bib0055","doi-asserted-by":"crossref","first-page":"239","DOI":"10.2147\/TCRM.S12701","article-title":"Clinical potential of lurasidone in the management of schizophrenia","volume":"7","author":"Samalin","year":"2011","journal-title":"Ther Clin Risk Manag"},{"issue":"1","key":"10.1016\/j.encep.2014.10.009_bib0060","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1124\/jpet.110.167346","article-title":"Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity","volume":"334","author":"Ishibashi","year":"2010","journal-title":"J Pharmacol Exp Ther"},{"issue":"7\u20138","key":"10.1016\/j.encep.2014.10.009_bib0065","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1345\/aph.1M721","article-title":"Lurasidone: an atypical antipsychotic for schizophrenia","volume":"46","author":"Risbood","year":"2012","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.encep.2014.10.009_bib0070","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.bbr.2013.01.026","article-title":"The role of 5-HT7 receptor antagonism in the amelioration of MK-801-induced learning and memory deficits by the novel atypical antipsychotic drug lurasidone","volume":"244","author":"Horisawa","year":"2013","journal-title":"Behav Brain Res"},{"issue":"5","key":"10.1016\/j.encep.2014.10.009_bib0075","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1002\/hup.2338","article-title":"Effect of food on the pharmacokinetics of lurasidone: results of two randomized, open-label, crossover studies","volume":"28","author":"Preskorn","year":"2013","journal-title":"Hum Psychopharmacol"},{"issue":"3","key":"10.1016\/j.encep.2014.10.009_bib0080","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s00213-012-2838-2","article-title":"Lurasidone in the treatment of schizophrenia: a 6-week, placebo-controlled study","volume":"225","author":"Ogasa","year":"2013","journal-title":"Psychopharmacology (Berl)"},{"issue":"6","key":"10.1016\/j.encep.2014.10.009_bib0085","doi-asserted-by":"crossref","first-page":"829","DOI":"10.4088\/JCP.08m04905","article-title":"Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial","volume":"70","author":"Nakamura","year":"2009","journal-title":"J Clin Psychiatry"},{"issue":"5","key":"10.1016\/j.encep.2014.10.009_bib0090","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.jpsychires.2013.01.020","article-title":"Lurasidone for the treatment of acutely psychotic patients with schizophrenia: a 6-week, randomized, placebo-controlled study","volume":"47","author":"Nasrallah","year":"2013","journal-title":"J Psychiatr Res"},{"key":"10.1016\/j.encep.2014.10.009_bib0095","series-title":"NCT00044044: a comparison of study drug with placebo and haloperidol in patients with schizophrenia","author":"Sunovion","year":"2014"},{"issue":"9","key":"10.1016\/j.encep.2014.10.009_bib0100","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1176\/appi.ajp.2011.10060907","article-title":"Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study","volume":"168","author":"Meltzer","year":"2011","journal-title":"Am J Psychiatry"},{"issue":"1\u20133","key":"10.1016\/j.encep.2014.10.009_bib0105","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.schres.2013.01.009","article-title":"Efficacy and safety of lurasidone 80mg\/day and 160mg\/day in the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled trial","volume":"145","author":"Loebel","year":"2013","journal-title":"Schizophr Res"},{"issue":"2\u20133","key":"10.1016\/j.encep.2014.10.009_bib0110","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.schres.2011.04.008","article-title":"Double-blind comparison of the safety and efficacy of lurasidone and ziprasidone in clinically stable outpatients with schizophrenia or schizoaffective disorder","volume":"132","author":"Potkin","year":"2011","journal-title":"Schizophr Res"},{"issue":"2","key":"10.1016\/j.encep.2014.10.009_bib0115","doi-asserted-by":"crossref","first-page":"170","DOI":"10.4088\/JCP.12m07992","article-title":"Effectiveness of lurasidone in patients with schizophrenia or schizoaffective disorder switched from other antipsychotics: a randomized, 6-week, open-label study","volume":"74","author":"McEvoy","year":"2013","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.encep.2014.10.009_bib0120","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.schres.2010.02.425","article-title":"Efficacy of lurasidone in schizophrenia: results of a pooled analysis based on a 5-factor model of schizophrenia","volume":"117","author":"Loebel","year":"2010","journal-title":"Schizophr Res"},{"key":"10.1016\/j.encep.2014.10.009_bib0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S1092852914000285","article-title":"Lurasidone for the treatment of depressive symptoms in schizophrenia: analysis of 4 pooled, 6-week, placebo-controlled studies","author":"Nasrallah","year":"2014","journal-title":"CNS Spectr"},{"issue":"1","key":"10.1016\/j.encep.2014.10.009_bib0130","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.schres.2003.07.001","article-title":"The relationship of neuropsychological test performance with the PANSS in antipsychotic naive, first-episode psychosis patients","volume":"68","author":"Good","year":"2004","journal-title":"Schizophr Res"},{"issue":"1\u20133","key":"10.1016\/j.encep.2014.10.009_bib0135","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.schres.2011.01.004","article-title":"Performance and interview-based assessments of cognitive change in a randomized, double-blind comparison of lurasidone vs. ziprasidone","volume":"127","author":"Harvey","year":"2011","journal-title":"Schizophr Res"},{"issue":"11","key":"10.1016\/j.encep.2014.10.009_bib0140","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/j.euroneuro.2013.08.003","article-title":"Effect of lurasidone on neurocognitive performance in patients with schizophrenia: a short-term placebo- and active-controlled study followed by a 6-month double-blind extension","volume":"23","author":"Harvey","year":"2013","journal-title":"Eur Neuropsychopharmacol"},{"issue":"2","key":"10.1016\/j.encep.2014.10.009_bib0145","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1017\/S1092852913000904","article-title":"Daytime sleepiness associated with lurasidone and quetiapine XR: results from a randomized double-blind, placebo-controlled trial in patients with schizophrenia","volume":"19","author":"Loebel","year":"2014","journal-title":"CNS Spectr"},{"issue":"Suppl. 1","key":"10.1016\/j.encep.2014.10.009_bib0150","first-page":"217","article-title":"Safety of lurasidone: pooled analysis of five placebo-controlled trials in patients with schizophrenia","volume":"13","author":"Cucchiaro","year":"2010","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.encep.2014.10.009_bib0155","series-title":"The Maudsley Prescribing Guidelines","author":"Taylor","year":"2009"},{"issue":"2","key":"10.1016\/j.encep.2014.10.009_bib0160","doi-asserted-by":"crossref","first-page":"76","DOI":"10.3371\/CSRP.6.2.5","article-title":"Lurasidone for the acute treatment of adults with schizophrenia: what is the number needed to treat, number needed to harm, and likelihood to be helped or harmed?","volume":"6","author":"Citrome","year":"2012","journal-title":"Clin Schizophr Relat Psychoses"},{"key":"10.1016\/j.encep.2014.10.009_bib0165","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jad.2013.10.040","article-title":"Clinical assessment of lurasidone benefit and risk in the treatment of bipolar I depression using number needed to treat, number needed to harm, and likelihood to be helped or harmed","volume":"155","author":"Citrome","year":"2014","journal-title":"J Affect Disord"},{"issue":"6","key":"10.1016\/j.encep.2014.10.009_bib0170","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1586\/14737175.2014.915741","article-title":"The effectiveness of lurasidone as an adjunct to lithium or divalproex in the treatment of bipolar disorder","volume":"14","author":"Alamo","year":"2014","journal-title":"Expert Rev Neurother"}],"container-title":["L'Enc\u00e9phale"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0013700614002322?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0013700614002322?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,28]],"date-time":"2018-09-28T01:21:18Z","timestamp":1538097678000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0013700614002322"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["S0013700614002322"],"URL":"https:\/\/doi.org\/10.1016\/j.encep.2014.10.009","relation":{},"ISSN":["0013-7006"],"issn-type":[{"value":"0013-7006","type":"print"}],"subject":[],"published":{"date-parts":[[2014,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacit\u00e9 et tol\u00e9rance \u00e0 court terme de la lurasidone dans la prise en charge de la schizophr\u00e9nie","name":"articletitle","label":"Article Title"},{"value":"L'Enc\u00e9phale","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.encep.2014.10.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 L\u2019Enc\u00e9phale, Paris. Published by Elsevier Masson SAS All rights reserved.","name":"copyright","label":"Copyright"}]}}